DE3587524T2 - Herstellung von chimären antikörpern. - Google Patents

Herstellung von chimären antikörpern.

Info

Publication number
DE3587524T2
DE3587524T2 DE85904274T DE3587524T DE3587524T2 DE 3587524 T2 DE3587524 T2 DE 3587524T2 DE 85904274 T DE85904274 T DE 85904274T DE 3587524 T DE3587524 T DE 3587524T DE 3587524 T2 DE3587524 T2 DE 3587524T2
Authority
DE
Germany
Prior art keywords
encodes
production
chimeric antibodies
molecule
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE85904274T
Other languages
English (en)
Other versions
DE3587524D1 (de
DE3587524T3 (de
Inventor
Michael Neuberger
Terence Rabbitts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10566192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3587524(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of DE3587524D1 publication Critical patent/DE3587524D1/de
Application granted granted Critical
Publication of DE3587524T2 publication Critical patent/DE3587524T2/de
Publication of DE3587524T3 publication Critical patent/DE3587524T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE3587524T 1984-09-03 1985-09-03 Herstellung von chimären antikörpern. Expired - Lifetime DE3587524T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848422238A GB8422238D0 (en) 1984-09-03 1984-09-03 Chimeric proteins
PCT/GB1985/000392 WO1986001533A1 (en) 1984-09-03 1985-09-03 Production of chimeric antibodies

Publications (3)

Publication Number Publication Date
DE3587524D1 DE3587524D1 (de) 1993-09-16
DE3587524T2 true DE3587524T2 (de) 1994-01-20
DE3587524T3 DE3587524T3 (de) 2002-06-20

Family

ID=10566192

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3587524T Expired - Lifetime DE3587524T3 (de) 1984-09-03 1985-09-03 Herstellung von chimären antikörpern.

Country Status (6)

Country Link
EP (1) EP0194276B2 (de)
JP (2) JP2714786B2 (de)
AT (1) ATE92959T1 (de)
DE (1) DE3587524T3 (de)
GB (2) GB8422238D0 (de)
WO (1) WO1986001533A1 (de)

Families Citing this family (1118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1986005513A1 (en) * 1985-03-18 1986-09-25 Gene Labs, Inc. Hybrid-gene cassette vector
US5169939A (en) * 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
AU606320B2 (en) * 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
EP0536566A1 (de) * 1985-11-01 1993-04-14 Xoma Corporation Modulare Einheit von Antikörpergenen, daraus hergestellte Antikörper und Verwendung
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
ATE143052T1 (de) * 1986-07-07 1996-10-15 Centocor Inc Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6121424A (en) * 1991-11-25 2000-09-19 Enzon, Inc. Multivalent antigen-binding proteins
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
CA1339445C (en) * 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3855869T2 (de) 1987-02-20 1997-10-02 Genentech Inc Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
DE3800048A1 (de) * 1987-05-14 1988-11-24 Boehringer Mannheim Gmbh Verfahren zur bestimmung eines antikoerpers in menschlichen koerperfluessigkeiten
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0623679B1 (de) * 1987-05-21 2003-06-25 Micromet AG Multifunktionelle Proteine mit vorbestimmter Zielsetzung
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
JPS6439990A (en) * 1987-08-05 1989-02-10 Chisso Corp Fused gene by bonding aequorin gene to functional gene
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5428133A (en) * 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
ATE140963T1 (de) * 1988-01-22 1996-08-15 Zymogenetics Inc Verfahren zur herstellung von sekretierten rezeptoranalogen
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
AU3342689A (en) * 1988-03-24 1989-10-16 Igen Incorporated Luminescent chimeric proteins
USRE39760E1 (en) * 1988-03-31 2007-08-07 International Bio-Immune Systems Inc. Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US4975369A (en) * 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US5906936A (en) * 1988-05-04 1999-05-25 Yeda Research And Development Co. Ltd. Endowing lymphocytes with antibody specificity
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
WO1990006323A2 (en) * 1988-11-29 1990-06-14 Centocor, Inc. Chimeric proteins incorporating a metal binding protein
DE3900534A1 (de) * 1989-01-10 1990-07-12 Boehringer Mannheim Gmbh Diagnostischer nachweis unter verwendung von chimaeren antikoerpern
US6309880B1 (en) * 1989-04-25 2001-10-30 Tanox, Inc. Antibodies specific for CD4-binding domain of HIV-1
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
IL94872A (en) * 1989-06-30 1995-03-30 Oncogen Monoclonal or chimeric antibodies that react with human carcinoma, recombinant proteins that contain their anti-binding site, pharmaceutical preparations and kits that contain the
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
US5314995A (en) * 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
EP0460607A3 (en) * 1990-06-05 1992-04-01 Bristol-Myers Squibb Company Novel monoclonal antibody to novel antigen associated with human tumors
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
US6399062B1 (en) * 1990-11-06 2002-06-04 The United States Of America As Represented By The Secretary Of The Navy Murine monoclonal antibody protective against Plasmodium vivax malaria
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
ES2236682T5 (es) * 1991-01-21 2011-03-31 Elan Pharmaceuticals, Inc. Ensayo y modelo para la enfermedad de alzheimer.
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
JP3213314B2 (ja) * 1991-04-05 2001-10-02 ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン 幹細胞因子レセプターに対するモノクローナル抗体
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
ATE188708T1 (de) * 1991-08-21 2000-01-15 Novartis Ag Antikörperderivate
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US5766886A (en) * 1991-12-13 1998-06-16 Xoma Corporation Modified antibody variable domains
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
JPH08510909A (ja) 1993-05-28 1996-11-19 ザ スクリップス リサーチ インスティチュート Ｃｄ１４媒介細胞活性化を抑制するための方法および組成物
US5674493A (en) * 1993-08-31 1997-10-07 Thomas Jefferson University Compositions and methods for targeting cells with A2R and A2R monoclonal antibodies
WO1995008336A1 (en) * 1993-09-22 1995-03-30 Nichols Institute Diagnostics Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
AU702293B2 (en) 1993-10-27 1999-02-18 Athena Neurosciences, Inc. Transgenic animals harboring APP allele having Swedish mutation
EP0749494A1 (de) 1994-03-07 1996-12-27 Chiron Corporation Zusammensetzungen zur hemmung der bildung von tnf und deren verwendungen
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
ATE407207T1 (de) 1994-11-02 2008-09-15 Trophix Pharm Inc Natrium-ionenkanäle spezifisch für das periphäre nervensystem, dna welche diese kodiert, wirkstoff-suche und methoden zu deren herstellung und verwendung
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US6091001A (en) * 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) * 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6015662A (en) * 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US5714352A (en) * 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6716974B1 (en) 1996-05-31 2004-04-06 Maine Medical Center Research Institute Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
AU720890B2 (en) 1996-05-31 2000-06-15 National American Red Cross, The Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
CA2257357C (en) 1996-06-07 2010-04-13 Neorx Corporation Humanized antibodies with modified glycosylation
US6268173B1 (en) 1996-07-12 2001-07-31 Institut Natural De La Sante Et La Recherche Medicale Polynucleotide encoding transcriptional intermediary factor-2
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2264200A1 (en) 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Human endokine alpha
AU734997B2 (en) * 1996-09-20 2001-06-28 General Hospital Corporation, The Composition and method for enhancing fibrinolysis using antibodies to alpha-2-antiplasmin
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
KR20050004269A (ko) 1996-10-25 2005-01-12 휴먼 게놈 사이언시즈, 인코포레이티드 뉴트로킨 알파
EP1780277A1 (de) 1997-01-15 2007-05-02 Yeda Research And Development Company, Ltd. IFN Rezeptor 1 bindende Proteine, dafür kodierende DNA und Verfahren zur Regulierung der zellulären Antwort auf Interferone
EP2060630B1 (de) 1997-04-10 2012-10-24 Stichting Katholieke Universiteit University Medical Centre Nijmegen PCA3, PCA3-Gene und Verfahren zu ihrer Verwendung
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
JP2001524824A (ja) 1997-04-16 2001-12-04 ミレニアム・フアーマシユーチカルズ・インコーポレーテツド Ｃｒｓｐタンパク質（システインに富む分泌性タンパク質）、それらをコードする核酸分子およびその用途
ES2330393T3 (es) 1997-04-25 2009-12-09 Antigenics Inc. Caracterizacion de ehrlichia granulocitica y metodos de uso.
DE69840998D1 (de) 1997-04-30 2009-09-03 Twinstrand Therapeutics Inc Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen
DK1015477T3 (da) 1997-05-30 2011-02-07 Human Genome Sciences Inc 32 humane sekreterede proteiner
CA2206774A1 (en) 1997-06-16 1998-12-16 Rick E. Preddie "prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
DE69841139D1 (de) 1997-07-14 2009-10-22 Univ Liege Mutationen im myostatingen steigern muskelmasse in säugetieren
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
WO1999023105A1 (en) 1997-11-03 1999-05-14 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
DE69841751D1 (en) 1997-11-21 2010-08-12 Human Genome Sciences Inc Chemokin alpha-5
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
JP2000000097A (ja) 1998-06-15 2000-01-07 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ結合蛋白質、該蛋白質をコードするＤＮＡ並びに該蛋白質に対するモノクローナル抗体
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
KR100618495B1 (ko) 1998-10-06 2006-08-31 마크 아론 에말파브 섬유상의 진균성 숙주 영역에서의 형질전환 시스템:크리소스포륨속에서
DE69839740D1 (de) 1998-10-22 2008-08-28 Univ Montana Vakzine enthaltend Omp85 Proteine von Neisseria gonorrhoeae und Neisseria meningitidis
MXPA01008098A (es) 1999-02-12 2002-10-23 Inst Genetics Llc Inmunoglobulina humanizada reactiva con moleculas b7 y metodo de tratamiento con el mismo.
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
EP1179000A4 (de) 1999-02-26 2005-10-12 Millennium Pharm Inc Ausscheidungsproteine und ihre verwendung
EP1161451A4 (de) 1999-02-26 2006-05-17 Human Genome Sciences Inc Menschliches alpha-endokin und verfahren zu seiner verwendung
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
IL130225A0 (en) 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP1196532A1 (de) 1999-07-27 2002-04-17 Unilever N.V. Bleichende waschmittelzusammensetzungen
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
DE60027027T2 (de) 1999-09-29 2006-11-30 Diagnocure Inc. Pca3 mrna in gutartigen und bösartigen prostatageweben
US7892541B1 (en) 1999-09-30 2011-02-22 Tumor Biology Investment Group, Inc. Soluble epidermal growth factor receptor isoforms
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
CA2897626C (en) 2000-02-11 2020-03-24 Biogen Idec Ma Inc. Heterologous polypeptide of the tnf family
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU5345901A (en) 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
US7632929B2 (en) 2000-04-20 2009-12-15 The Board Of Trustees Of The University Of Arkansas Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
ES2343351T3 (es) 2000-06-08 2010-07-29 Immune Disease Institute, Inc. Procedimientos y composiciones para inhibir la lesion por reperfusion mediada por inmunoglobulina.
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
JP2003000268A (ja) 2000-08-25 2003-01-07 Pfizer Prod Inc 血管新生にかかわる疾患を診断および治療するための方法および組成物
AU8847801A (en) 2000-08-25 2002-03-04 Basf Plant Science Gmbh Plant polynucleotides encoding novel prenyl proteases
WO2002018583A2 (en) 2000-09-01 2002-03-07 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2429625C (en) 2000-10-18 2012-05-01 Robert Sackstein Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof
AU2001297872B2 (en) 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
NZ526617A (en) 2000-11-28 2004-09-24 Wyeth Corp Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
PL365605A1 (en) 2000-11-28 2005-01-10 Wyeth Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
ATE506075T1 (de) 2000-12-08 2011-05-15 Curagen Corp Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
WO2002050123A2 (en) 2000-12-19 2002-06-27 Unilever N.V. Stabilization of antibodies or fragments thereof
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
CA2438943C (en) 2001-02-23 2019-05-14 Dana-Farber Cancer Institute, Inc. Hin-1, a tumor suppressor gene
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
MXPA03008959A (es) 2001-04-02 2004-10-15 Wyeth Corp Pd-1, un receptor para b7-4 y sus usos.
CA2444133A1 (en) 2001-04-16 2002-10-24 Wyeth Holdings Corporation Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US7745398B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
ATE440869T1 (de) 2001-06-20 2009-09-15 Fibron Ltd Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
LT1434871T (lt) 2001-09-20 2017-04-10 Immunex Corporation Heteromerinius polipeptidus ekspresuojančių ląstelių atranka
EP1432431B1 (de) 2001-10-04 2017-05-10 Genetics Institute LLC Verfahren und zusammensetzungen zur modulierung der wirkung des interleukin-21
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE10151511A1 (de) 2001-10-18 2003-05-08 Basf Lynx Bioscience Ag ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
EP1944043A1 (de) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Nukleinsäure- und Aminosäuresequenzen von Affen-Adenoviren, hergeleitete Vektoren und Verwendungsverfahren.
ATE517855T1 (de) 2001-11-30 2011-08-15 Biogen Idec Inc Antikörper gegen chemotaktische monozytenproteine
EP1542719A4 (de) 2001-12-05 2006-06-21 Baylor College Medicine Verfahren und zusammensetzungen zur steuerung der knochenbildung über modulation des sympathikotonus
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
EP1458754B1 (de) 2001-12-18 2009-12-09 Endocube SAS Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
EP1463807A4 (de) 2001-12-19 2006-04-12 Bristol Myers Squibb Co Formiatdehydrogenase aus pichia pastoris und verwendungen dafür
US7465553B2 (en) 2001-12-31 2008-12-16 Dana-Farber Cancer Institute, Inc. Psoriasin expression by breast epithelial cells
CA2477675C (en) 2002-03-05 2013-05-21 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
EP1499352A4 (de) 2002-04-12 2006-10-11 Medimmune Inc Rekombinante anti-interleukin-9-antikörper
JP2006511194A (ja) 2002-05-02 2006-04-06 デイビッド ラブジョイ テネウリンｃ末端関連ペプチド（ｔｃａｐ）並びにこれらに関連する方法および使用
ATE473284T1 (de) 2002-05-14 2010-07-15 Martek Biosciences Corp Carotinsynthase-gen und dessen verwendung
ES2370710T3 (es) 2002-05-28 2011-12-22 Ucb Pharma, S.A. ISÓMERO POSICIONAL DE PEG DE UN ANTICUERPO ANTI-TNFalfa (CDP870).
EP2070949B1 (de) 2002-06-10 2013-01-16 Vaccinex, Inc. C35-Antikörper und ihre Verwendung zur Behandlung von Krebs
AU2003247551C1 (en) 2002-06-17 2010-12-09 Thrasos Innovation, Inc. Single domain TDF-related compounds and analogs thereof
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
ES2556641T3 (es) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
US7906620B2 (en) 2002-08-16 2011-03-15 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
JP2006514823A (ja) 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
NZ541504A (en) 2002-11-13 2009-04-30 Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein E and methods of use
EP2112229A3 (de) 2002-11-25 2009-12-02 Sequenom, Inc. Verfahren zum Identifizieren des Brustkrebsrisikos und zugehörige Behandlungen
JP5717937B2 (ja) 2002-12-06 2015-05-13 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害療法を用いた患者の同定、判定および治療方法
ES2429338T3 (es) 2002-12-23 2013-11-14 Vical Incorporated Vacuna basada en polinucleótidos optimizados por codones contra infección por citomegalovirus humano
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
US20050265992A1 (en) 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
JP2006525792A (ja) 2003-01-17 2006-11-16 ザ ジョンズ ホプキンス ユニバーシティー Ｇｔｒａｐ３−１８を用いた細胞グリコシル化のモジュレーターを同定する方法
US9259459B2 (en) 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
CN1767852B (zh) 2003-01-31 2010-04-14 塞尔德克斯医疗公司 抗体疫苗缀合物及其用途
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
SE0301087D0 (sv) 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
PT2829283T (pt) 2003-04-30 2017-09-08 Univ Zuerich Método para tratamento do cancro utilizando uma imunotoxina
PL2374819T3 (pl) 2003-05-12 2017-09-29 Helion Biotech Aps Przeciwciała przeciwko MASP-2
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
CA2542232A1 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
WO2005012526A1 (en) 2003-08-04 2005-02-10 The Hospital For Sick Children Lafora's disease gene
EP2051077A3 (de) 2003-10-07 2009-05-27 Millennium Pharmaceuticals, Inc. Nucleinsäuremoleküle und Proteine zur Identifizierung, Beurteilung, Vorbeugung und Therapie von Eierstockkrebs
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
KR101438983B1 (ko) 2003-11-06 2014-09-05 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005047475A2 (en) 2003-11-11 2005-05-26 Regents Of The University Of Minnesota Regulation of cell membrane-mediated effects
EP1687026B1 (de) 2003-11-21 2008-05-14 UCB Pharma, S.A. Verfahren zur behandlung von multipler sklerose durch hemmung der il-17-aktivität
JP2007521248A (ja) 2003-12-10 2007-08-02 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヒト化抗ｃｃｒ２抗体および該抗体を使用する方法
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
WO2005063992A1 (ja) 2003-12-30 2005-07-14 Suntory Limited 新規血清型のストレプトコッカス ミュータンスおよびその利用
HUE026132T2 (en) 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses
US20060014211A1 (en) 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
ES2330860T3 (es) 2004-01-22 2009-12-16 Merck Patent Gmbh Anticuerpos anticancerosos con fijacion del complemento reducida.
AU2005320349C1 (en) 2004-02-06 2019-06-13 E. R. Squibb & Sons, L.L.C. Antibodies against clostridium difficile toxins and uses thereof
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
EP1713503B1 (de) 2004-02-10 2013-07-31 The Regents of the University of Colorado, a Body Corporate Hemmung von faktor b, dem alternativen komplement-pfad und relevante verfahren
WO2005085288A2 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research Natural igm antibodies and inhibitors thereof
EP2287194B1 (de) 2004-03-12 2016-10-26 Vasgene Therapeutics, Inc. EphB4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
EP1756162A1 (de) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Rezeptor-kupplungsmittel und ihre therapeutischen verwendungen
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US8318905B2 (en) 2004-04-23 2012-11-27 Richard Kroczek Antibodies for depletion of ICOS-positive cells in vivo
WO2005115435A2 (en) 2004-04-30 2005-12-08 Bas Medical, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
EP1598428A1 (de) 2004-05-18 2005-11-23 Georg Dewald Verfahren und Kits zum Nachweis von erblichen angioedema typ III
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
CN103356636A (zh) 2004-05-23 2013-10-23 杰勒德·M·豪斯 Theramutein调节剂
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Ｔａｇ-72에 대한 인간화 항체
WO2006009836A2 (en) 2004-06-17 2006-01-26 Thrasos Therapeutics, Inc. Tdf-related compounds and analogs thereof
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
US7973134B2 (en) 2004-07-07 2011-07-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
CA2574654C (en) 2004-07-22 2014-02-18 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7935790B2 (en) 2004-10-04 2011-05-03 Cell Singaling Technology, Inc. Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
WO2006042237A2 (en) 2004-10-06 2006-04-20 Mayo Foundation For Medical Education And Research B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
NZ554520A (en) 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
US7807789B2 (en) 2004-12-21 2010-10-05 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
AU2006214384A1 (en) 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation
EP1695981A1 (de) 2005-02-25 2006-08-30 Forschungsverbund Berlin e.V. Verfahren zum Redox-Potential-abhängigen Nachweis von Targetmolekülen durch wechselwirkende Polypeptide
EP2535355B1 (de) 2005-03-23 2019-01-02 Genmab A/S Antikörper gegen CD38 zur Behandlung von multiplem Myelom
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
WO2006117782A2 (en) 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
AU2006247188A1 (en) 2005-05-18 2006-11-23 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against chlamydia infection
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
CN101227924A (zh) 2005-05-26 2008-07-23 科罗拉多大学评议会 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
CA2608504A1 (en) 2005-05-31 2006-12-07 Duska Scientific Co. Inhibition of neuronal damage
WO2006138429A2 (en) 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
CN101365722A (zh) 2005-06-17 2009-02-11 艾兰制药国际有限公司 纯化抗Aβ抗体的方法
SI1899378T1 (sl) 2005-06-21 2010-02-26 Xoma Technology Ltd IL-1Beta vezavna protitelesa in njihovi fragmenti
EP3498289A1 (de) 2005-07-07 2019-06-19 Seattle Genetics, Inc. Monomethylvalinverbindungen mit phenylalaninseitenkettenmodifikationen am c-terminus
ES2908458T3 (es) 2005-07-18 2022-04-29 Seagen Inc Conjugados de fármaco-enlazador de beta-glucurónido
JP2009501913A (ja) 2005-07-21 2009-01-22 ゲンマブ エー／エス Ｆｃ受容体と結合する抗体原薬に関する効力アッセイ
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
EP1934867A2 (de) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagentien zum nachweis der proteinphosphorylierung in leukämie-signalwegen
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
DE602006021768D1 (de) 2005-09-28 2011-06-16 Dickinson & Co Nachweis von lysophosphatidylcholin für die prognose oder diagnose eines systemischen entzündungszustands
KR101472250B1 (ko) 2005-10-12 2014-12-11 모르포시스 아게 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
ES2526705T3 (es) 2005-10-25 2015-01-14 The Johns Hopkins University Métodos y composiciones para el tratamiento de síndrome de Marfan y trastornos asociados
WO2007089303A2 (en) 2005-11-01 2007-08-09 Abbott Biotechnology Ltd. Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
EP2455100A3 (de) 2005-11-07 2012-11-07 The Rockefeller University Reagenzien, Verfahren und System zur Auswahl eines zytotoxischen Antikörpers oder einer Variante davon
EA014900B1 (ru) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
US9415107B2 (en) 2005-11-10 2016-08-16 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
US7807790B2 (en) 2005-11-14 2010-10-05 Metamol Theranostics, Llc Peptide sequence that promotes tumor invasion
PT1960430E (pt) 2005-12-09 2015-01-05 Ucb Pharma Sa Moléculas de anticorpo com especificidade para il-6 humana
WO2007070750A1 (en) 2005-12-13 2007-06-21 Eli Lilly And Company Anti-il-17 antibodies
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8716033B2 (en) 2006-02-10 2014-05-06 Life Technologies Corporation Oligosaccharide modification and labeling of proteins
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
BRPI0708909B8 (pt) 2006-03-15 2021-05-25 Alexion Pharma Inc uso de um anticorpo que se liga a c5 para tratar um paciente que sofre de hemoglobinúria paroxística noturna
PL2374472T3 (pl) 2006-03-16 2018-11-30 Dyax Corp. Kompozycje i sposoby leczenia zaburzeń okulistycznych
EP2163563A1 (de) 2006-03-31 2010-03-17 Massachusetts Institute of Technology Behandlung von Tumoren, die mutierte EGF-Rezeptoren exprimieren
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
EP2708242A3 (de) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Anwendungen und Zusammensetzungen zur Behandlung von Morbus Bechterew
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
MX2008013363A (es) 2006-04-20 2009-03-26 Jackson H M Found Military Med Metodos y composiciones basados en la proteina tipo 1 de la toxina shiga.
EP2023722A4 (de) 2006-05-15 2012-01-18 Univ Kentucky Toll-like-rezeptor (tlr)-stimulierung für okulare angiogenese und maculadegeneration
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US20080138334A1 (en) 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US8153369B2 (en) 2006-06-05 2012-04-10 Cancer Care Ontario Assessment of risk for colorectal cancer
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
US7858756B2 (en) 2006-06-15 2010-12-28 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
PT2193801E (pt) 2006-06-28 2012-02-28 Yeda Res & Dev Caspase-8 e tratamento de inflamação, infecção e cicatrização de ferida
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
BRPI0713802A2 (pt) 2006-06-30 2012-11-06 Abbott Biotech Ltd dispositivo de injeção automático
CA2656620C (en) 2006-07-04 2018-03-13 Genmab A/S Cd20 binding molecules for the treatment of copd
EP2059531A1 (de) 2006-07-07 2009-05-20 Intercell AG Kleine streptococcus-pyogenes-antigene und anwendung davon
AU2007272957B2 (en) 2006-07-13 2014-05-01 Wyeth Llc Production of glycoproteins
EP2420252A1 (de) 2006-08-04 2012-02-22 Novartis AG EPHB3-spezifischer Antikörper und Verwendungen davon
US7939636B2 (en) 2006-08-11 2011-05-10 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in c-Src signaling pathways
ME00588A (en) 2006-08-18 2011-12-20 Prlr-specific antibody and uses thereof
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
NZ575018A (en) 2006-09-05 2012-04-27 Alexion Pharma Inc Compositions for the treatment of antibody mediated neuropathies
EP2500416A1 (de) 2006-09-13 2012-09-19 Abbott Laboratories Verbesserungen an Zellkulturen
KR20090074040A (ko) 2006-09-13 2009-07-03 아보트 러보러터리즈 세포 배양의 개선
NZ576122A (en) 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
CN101522219A (zh) 2006-10-12 2009-09-02 惠氏公司 改变抗体溶液中离子强度以减少乳光/聚集物
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
JP5732182B2 (ja) 2006-10-27 2015-06-10 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． 眼疾患と症状を処置するための組成物および方法
ES2524059T3 (es) 2006-10-27 2014-12-03 Lpath, Inc. Composiciones y procedimientos de unión a esfingosina-1-fosfato
EP2064315B1 (de) 2006-11-03 2015-05-13 Wyeth LLC Glycolysehemmstoffe in zellkulturen
WO2008060448A2 (en) 2006-11-10 2008-05-22 Massachusetts Institute Of Technology Small molecule pak inhibitors
EP2094282A4 (de) 2006-11-15 2010-05-05 Functional Genetics Inc Antikörper gegen tsg101 und verwendungen davon zur behandlung von virusinfektionen
EP2609932B1 (de) 2006-12-01 2022-02-02 Seagen Inc. Veränderliche target-bindemittel und verwendungen davon
ES2435437T3 (es) 2006-12-07 2013-12-19 Novartis Ag Anticuerpos antagonistas contra Ephb3
US8105602B2 (en) 2006-12-08 2012-01-31 Tactic Pharma, Llc Urokinase-type plasminogen activator receptor epitope, monoclonal antibodies derived therefrom and methods of use thereof
EP2102366A4 (de) 2006-12-10 2010-01-27 Dyadic International Inc Expression und hochdurchsatz-screening komplexer exprimierter dna-bibliotheken bei fadenpilzen
EP2094306A2 (de) 2006-12-20 2009-09-02 XOMA Technology Ltd. Behandlung von il-1-beta-bedingten erkrankungen
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2533566T3 (es) 2006-12-29 2015-04-13 The Regents Of The University Of Colorado, A Body Corporate Diana diagnóstica y terapéutica para enfermedades autoinmunitarias y sus usos
WO2008086002A2 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Slco1b3 genotype
EP2269625A3 (de) 2007-01-12 2012-08-08 Intercell AG Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür
EP2120915B1 (de) 2007-01-22 2011-09-28 Genentech, Inc. Abscheidung von polyelektrolyten und reinigung von antikörpern
US8168415B2 (en) 2007-02-07 2012-05-01 The Regents Of The University Of Colorado Axl fusion proteins as Axl tyrosine kinase inhibitors
JP5662684B2 (ja) 2007-02-16 2015-02-04 ジェンザイム コーポレーション 甲状腺障害リスクの同定方法
EP2447719B1 (de) 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteine
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2924113B1 (de) 2007-03-02 2019-04-10 Wyeth LLC Verwendung von kupfer und glutamat in zellkulturen zur herstellung von polypeptiden
EP2079839A4 (de) 2007-03-05 2009-11-18 Cancer Care Ontario Abschätzung des kolorektalkarzinomrisikos
EP1972639A3 (de) 2007-03-07 2008-12-03 Cell Signaling Technology, Inc. Reagenzien zur Erkennung von Proteinphosphorylierung in Karzinom-Signalwegen
EP1975184A3 (de) 2007-03-26 2008-11-26 Cell Signaling Technology, Inc. Serin- oder Threonin-Phosphorylationsorte
EP1983002A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylations-Stellen und spezifische Antikörper
EP1983003A3 (de) 2007-04-19 2009-03-11 Peter Hornbeck Tyrosinphosphorylationsstellen und spezifische Antikörper
US7977462B2 (en) 2007-04-19 2011-07-12 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2140263B1 (de) 2007-04-20 2017-01-04 The Board of Trustees of The University of Arkansas Haptenverbindungen und zusammensetzungen sowie ihre verwendung
US20090053831A1 (en) 2007-05-01 2009-02-26 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
EP2338902A1 (de) 2007-05-02 2011-06-29 Intercell AG Klebsiella-Antigene
US8962273B2 (en) 2007-05-11 2015-02-24 Genzyme Corporation Methods of producing a secreted protein
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US8158124B2 (en) 2007-05-30 2012-04-17 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
EP4119579A1 (de) 2007-05-31 2023-01-18 Genmab A/S Stabile igg4-antikörper
EP2171451A4 (de) 2007-06-11 2011-12-07 Abbott Biotech Ltd Verfahren zur behandlung juveniler idiopathischer arthritis
US20080317768A1 (en) 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
EP2185688A4 (de) 2007-08-06 2010-08-25 Burnham Inst Medical Research Znf206: ein neuer regulator der selbsterneuerung und pluripotenz embryonaler stammzellen
EP2185594B1 (de) 2007-08-13 2016-04-06 VasGene Therapeutics, Inc. Behandlung von krebs unter verwendung von humanisierten, an ephb4 bindenden antikörpern
WO2009033071A2 (en) 2007-09-07 2009-03-12 Dyadic International, Inc. Novel fungal enzymes
CA2698809C (en) 2007-09-14 2023-10-17 Amgen Inc. Homogeneous antibody populations
EP2567969A1 (de) 2007-09-24 2013-03-13 Cornell University Immunogene Proteine aus der genombasierten äußeren Membran von Leptospira sowie darauf basierende Zusammensetzungen und Verfahren
NZ584642A (en) 2007-09-27 2012-08-31 Japan Tobacco Inc Factor involved in latent infection with herpesvirus, and use thereof
GB0719231D0 (en) 2007-10-03 2007-11-14 Oxford Genome Sciences Uk Ltd Protein
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
EA201692127A1 (ru) 2007-11-07 2017-08-31 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческим dec-205
EP2902495B1 (de) 2007-11-09 2019-12-25 The Salk Institute for Biological Studies Verwendung von Tam-Rezeptor-Aktivatoren als Immunsuppressiva
EP2062920A3 (de) 2007-11-21 2009-06-17 Peter Hornbeck Proteinphosphorylation durch basophilische Serin-/Threonin-Kinasen in Insulinsignalisierungspfaden
US8815237B2 (en) 2007-12-05 2014-08-26 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
CA2710252C (en) 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
AU2008345022B2 (en) 2007-12-28 2014-11-06 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
JP5511684B2 (ja) 2008-01-11 2014-06-04 アドヘロン セラピューティクス，インコーポレイテッド 炎症性関節障害を治療するためのカドヘリン−１１ｅｃｌドメインアンタゴニスト
JP2011518313A (ja) 2008-01-15 2011-06-23 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 急性骨髄性白血病幹細胞のマーカー
EP2245052B1 (de) 2008-01-25 2017-05-24 Aarhus Universitet Selektive exosite-inhibierung der papp-a-aktivität gegenüber igfbp-4
WO2009115508A2 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
PL2842575T3 (pl) 2008-03-18 2018-02-28 Seattle Genetics, Inc. Koniugaty aurystatyny lek łącznik
EP2274437B1 (de) 2008-04-10 2015-12-23 Cell Signaling Technology, Inc. Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
ES2836128T3 (es) 2008-04-16 2021-06-24 Univ Johns Hopkins Método para determinar variantes del receptor de andrógenos en cáncer de próstata
ES2651924T3 (es) 2008-04-18 2018-01-30 The General Hospital Corporation Inmunoterapias que emplean vacunas autoensamblantes
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
CN102316894A (zh) 2008-06-20 2012-01-11 惠氏有限责任公司 来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
TR201808591T4 (tr) 2008-06-25 2018-07-23 Esbatech Alcon Biomed Res Unit Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması.
ES2464459T3 (es) 2008-06-25 2014-06-02 H. Lundbeck A/S Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor
ES2687259T5 (es) 2008-06-25 2022-10-14 Novartis Ag Anticuerpos estables y solubles que inhiben TNF
CA2729961C (en) 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
US8148088B2 (en) 2008-07-18 2012-04-03 Abgent Regulation of autophagy pathway phosphorylation and uses thereof
EP2344180A2 (de) 2008-09-23 2011-07-20 Wyeth LLC Verfahren zur vorhersage der produktion von aktivierenden signalen durch vernetzende bindungsproteine
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP2346525A4 (de) 2008-10-02 2012-05-09 Celtaxsys Inc Verfahren zur modulation der negativen chemotaxis von immunzellen
EP2340038B1 (de) 2008-10-10 2018-01-10 Children's Medical Center Corporation Biochemisch stabilisierter hiv-1-env-trimer-impfstoff
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
MX345226B (es) 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
RU2553214C2 (ru) 2008-10-29 2015-06-10 Аблинкс Н.В. Способы очистки однодоменных антигенсвязывающих молекул
DK3199553T3 (da) 2008-10-29 2019-07-22 Circular Commitment Company Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom
NZ614064A (en) 2008-11-05 2015-04-24 Wyeth Llc Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
CA2744555A1 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
CN102325790A (zh) 2008-12-03 2012-01-18 西马生物医学计划公司 应用酚可溶性调控蛋白研制疫苗
US8401799B2 (en) 2008-12-05 2013-03-19 Lpath, Inc. Antibody design using anti-lipid antibody crystal structures
CN105641694B (zh) 2008-12-19 2020-08-14 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
CA2748757A1 (en) 2008-12-31 2010-07-08 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
AU2010207552A1 (en) 2009-01-21 2011-09-01 Oxford Biotherapeutics Ltd. PTA089 protein
US8313915B2 (en) 2009-01-21 2012-11-20 Gundersen Lutheran Medical Foundation, Inc. Early detection of canine lyme disease by specific peptides and antibodies
WO2010088522A2 (en) 2009-01-30 2010-08-05 Ab Biosciences, Inc. Novel lowered affinity antibodies and uses therefor
WO2010091182A2 (en) 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
US20110306069A1 (en) 2009-02-19 2011-12-15 Qingyu Wu Corin As A Marker For Heart Failure
EP2403530B1 (de) 2009-02-27 2016-05-11 Massachusetts Institute of Technology Manipulierte proteine mit hoher affinität für dota-chelate
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
JP2010213694A (ja) 2009-03-12 2010-09-30 Wyeth Llc ＰＫＮ３／ＲｈｏＣ高分子複合体およびその使用方法
JP2012522749A (ja) 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗ｉｌ−２３免疫グロブリン
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP2990051B1 (de) 2009-04-10 2016-10-26 Tufts Medical Center, Inc. Par-1-aktivierung mittels metalloproteinase-1 (mmp-1)
KR20110138412A (ko) 2009-04-16 2011-12-27 애보트 바이오테라퓨틱스 코포레이션 항-ΤΝＦ-α 항체 및 그의 용도
WO2010121093A2 (en) 2009-04-17 2010-10-21 Lpath, Inc. Humanized antibody compositions and methods for binding lysophosphatidic acid
BRPI1016204A2 (pt) 2009-04-22 2016-04-19 Merck Patent Gmbh proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
EP3524275A1 (de) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
ES2702049T3 (es) 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
EP2424891B1 (de) 2009-04-29 2014-06-11 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Monoklonale erg-antikörper
US8617554B2 (en) 2009-05-13 2013-12-31 Genzyme Corporation Anti-human CD52 immunoglobulins
SG177265A1 (en) 2009-06-17 2012-02-28 Abbott Biotherapeutics Corp Anti-vegf antibodies and their uses
AU2010270894A1 (en) 2009-06-24 2012-02-09 Lpath, Inc. Methods of increasing neuronal differntiation using antibodies to lysophoshatidic acid
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
EP2272979A1 (de) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
CA2766861A1 (en) 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
WO2011048598A1 (en) 2009-10-22 2011-04-28 Yeda Research And Development Co. Ltd. Compositions and methods for treating aspergillosis
CA2777825A1 (en) 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
US9588121B2 (en) 2009-11-06 2017-03-07 Go Therapeutics, Inc. Method for early detection of cancer
CA2778953C (en) 2009-11-13 2020-01-14 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
WO2011068870A2 (en) 2009-12-01 2011-06-09 President And Fellows Of Harvard College Modulation of nk cell antigen specific effector activity by modulation of cxcr6 (cd186)
JP6018917B2 (ja) 2009-12-07 2016-11-02 デシミューン セラピューティクス，インコーポレイテッド 抗炎症抗体およびその使用
CA2781725A1 (en) 2009-12-16 2011-06-23 Philip Bosch Methods of treating interstitial cystitis
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
CA2787685A1 (en) 2010-01-22 2011-07-28 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
JP6101489B2 (ja) 2010-01-28 2017-03-22 アブ バイオサイエンシズ インコーポレイテッド 親和性が低下した抗体およびそれを作製する方法
JP2013518590A (ja) 2010-02-02 2013-05-23 アボツト・バイオテクノロジー・リミテツド ＴＮＦ−α阻害剤を用いる処置に対する応答性を予測するための方法および組成物
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
BR112012022229A2 (pt) 2010-03-03 2016-07-05 Univ British Columbia epítopo beta amilóide epecíficio para oligômero e anticorpos
EP2545078A1 (de) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1-antikörper
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2550529B1 (de) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
US10472426B2 (en) 2010-03-25 2019-11-12 Ucb Biopharma Sprl Disulfide stabilized DVD-Ig molecules
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
EP2552947A4 (de) 2010-03-26 2013-11-13 Dartmouth College Vista-regulatorisches t-zellen-mediator-protein, vista-bindende wirkstoffe und verwendung davon
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CA2793778A1 (en) 2010-04-05 2011-11-13 Wyeth Llc Biomarkers for p13k-driven cancer
HUE035098T2 (en) 2010-04-16 2018-05-02 Biogen Ma Inc Anti-VLA4 Antibodies
NZ602782A (en) 2010-04-21 2015-07-31 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
EP2380909A1 (de) 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. An Brustkrebs beteiligtes Protein PTK-7
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
US8747854B2 (en) 2010-06-03 2014-06-10 Abbvie Biotechnology Ltd. Methods of treating moderate to severe hidradenitis suppurativa with anti-TNF-alpha antibodies
EP3327035A1 (de) 2010-06-22 2018-05-30 Precision Biologics Inc. Für dickdarm- und bauchspeicheldrüsenkrebs spezifische antigene und antikörper
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
LT2593128T (lt) 2010-07-15 2018-06-25 Adheron Therapeutics, Inc. Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai
CA2805572A1 (en) 2010-07-16 2012-01-19 Martin Hegen Modified single domain antigen binding molecules and uses thereof
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
EP2420250A1 (de) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4-Antikörper
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
EP2606119A1 (de) 2010-08-20 2013-06-26 Wyeth LLC Zellkultur aus wachstumsfaktorfreien adaptierten zellen
MY171312A (en) 2010-08-23 2019-10-08 Univ Texas Anti-ox40 antibodies and methods of using the same
HRP20210242T4 (hr) 2010-08-23 2024-05-10 Wyeth Llc Stabilne formulacije antigena iz bakterije neisseria meningitidis rlp2086
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
CA3182320A1 (en) 2010-09-23 2012-03-29 Precision Biologics, Inc. Colon and pancreas cancer peptidomimetics
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
EP2632489B1 (de) 2010-10-27 2020-01-15 The Research Foundation for The State University of New York Zusammensetzungen zur anzielung der löslichen extrazellulären domäne von e-cadherin sowie zugehörige krebstherapieverfahren
WO2012064743A2 (en) 2010-11-08 2012-05-18 The Johns Hopkins University Methods for improving heart function
EP2640425A2 (de) 2010-11-18 2013-09-25 Beth Israel Deaconess Medical Center, Inc. Verfahren zur behandlung von adipositas durch hemmung von nicotinamid-n-methyl-transferase (nnmt)
BR112013012396A2 (pt) 2010-11-19 2020-11-10 Toshio Imai anticorpos anti-ccl20 de neutralização
PT2643352T (pt) 2010-11-23 2018-08-01 Glaxo Group Ltd Proteínas de ligação a antigénio para a oncostatina m (osm)
CA2818813C (en) 2010-11-23 2020-10-06 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of oral mucositis
WO2012071513A2 (en) 2010-11-24 2012-05-31 Hong Gao Expanding hematopoietic stem cells
GB2502462B (en) 2011-01-10 2018-08-08 Univ Michigan Regents Stem cell factor inhibitor
LT2663577T (lt) 2011-01-14 2017-07-25 Ucb Biopharma Sprl Antikūnas, surišantis il-17a ir il-17f
EP2749305B1 (de) 2011-01-24 2017-11-01 AbbVie Biotechnology Ltd Automatische Injektionsvorrichtungen mit umspritzten Greifflächen
EP2680925B1 (de) 2011-03-02 2019-11-20 Berg LLC Interrogatorische zellbasierte assays und verwendung derselben
WO2012131053A1 (en) 2011-03-30 2012-10-04 Ablynx Nv Methods of treating immune disorders with single domain antibodies against tnf-alpha
AU2012239961A1 (en) 2011-04-08 2013-10-24 Biogen Ma Inc. Biomarkers predictive of therapeutic responsiveness to IFNbeta and uses thereof
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
US9956345B2 (en) 2011-04-21 2018-05-01 Abbvie Inc. Wearable automatic injection device for controlled administration of therapeutic agents
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
PE20141672A1 (es) 2011-05-02 2014-11-26 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-alfa4�7
US20140086827A1 (en) 2011-05-09 2014-03-27 The Cleveland Clinic Foundation Serum S100B And Uses Thereof
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
CA2837184C (en) 2011-05-25 2021-09-21 Innate Pharma, S.A. Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
EP2537933A1 (de) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Auf IL-15- und IL-15Ralpha-Sushi-Domäne basierende Immunozytokine
RS55716B1 (sr) 2011-06-28 2017-07-31 Oxford Biotherapeutics Ltd Terapeutski i dijagnostički cilj
DK2726101T3 (en) 2011-06-30 2018-12-03 Genzyme Corp T-CELL ACTIVATION INHIBITORS
EP2546267A1 (de) 2011-07-13 2013-01-16 UCB Pharma S.A. Bakterienwirtsstamm mit rekombinanter DsbC-Expression
EP3339325A1 (de) 2011-07-13 2018-06-27 UCB Biopharma SPRL Bakterienwirtsstamm zur expression von rekombinanter dsbc
US20150125533A1 (en) 2011-07-25 2015-05-07 American University In Cairo Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
SG10201804809RA (en) 2011-08-22 2018-07-30 Cnj Holdings Inc Clostridium difficile antibodies
AU2012298884B2 (en) 2011-08-23 2017-11-16 Foundation Medicine, Inc. Novel KIF5B-RET fusion molecules and uses thereof
AU2012304635B2 (en) 2011-09-06 2017-08-31 Translational Sciences Inc. SerpinF2-binding molecules and methods of use
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
WO2013039996A1 (en) 2011-09-13 2013-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
EP2771349B1 (de) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatikverfahren zur bestimmung von peptidbindungen
PT2758432T (pt) 2011-09-16 2019-06-14 Ucb Biopharma Sprl Anticorpos neutralizantes contra as exotoxinas principais tcda e tcdb de clostridium difficile
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
WO2013055911A1 (en) 2011-10-14 2013-04-18 Dana-Farber Cancer Institute, Inc. Znf365/zfp365 biomarker predictive of anti-cancer response
WO2013057628A1 (en) 2011-10-21 2013-04-25 Pfizer Inc. Addition of iron to improve cell culture
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
RU2586885C2 (ru) 2011-11-17 2016-06-10 Пфайзер Инк. Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство
EP2783214A2 (de) 2011-11-23 2014-10-01 The Board of Regents of The University of Texas System Proteomischer nachweis von antikörpern
EP2599496A1 (de) 2011-11-30 2013-06-05 Kenta Biotech AG Neuartige Targets von Acinetobacter baumannii
EP2794657B1 (de) 2011-12-19 2017-10-11 Xoma (Us) Llc Verfahren zur behandlung von akne
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
EP2820047B1 (de) 2012-03-01 2018-04-25 Amgen Research (Munich) GmbH Langlebige polypeptidbindungsmoleküle
BR122016004924A2 (pt) 2012-03-09 2019-07-30 Pfizer Inc. Polipeptídeo isolado e composições imunogênicas compreendendo os mesmos
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN104350156B (zh) 2012-03-27 2019-04-02 弗·哈夫曼-拉罗切有限公司 用于重组蛋白质的改进的收获操作
WO2013150518A1 (en) 2012-04-01 2013-10-10 Rappaport Family Institute For Research In The Medical Sciences Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
EP2834641A1 (de) 2012-04-02 2015-02-11 Gundersen Lutheran Health Systems, Inc. Reagenzien, verfahren und kits zur klassifizierung von krebs
SG10201608234UA (en) 2012-04-02 2016-11-29 Berg Llc Interrogatory cell-based assays and uses thereof
US9494597B2 (en) 2012-04-02 2016-11-15 Ab Biosciences, Inc. Human control antibodies and uses therefor
NZ702178A (en) 2012-05-14 2017-01-27 Biogen Ma Inc Lingo-2 antagonists for treatment of conditions involving motor neurons
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
CN108465112B (zh) 2012-05-15 2022-04-29 西雅图基因公司 自稳定接头偶联物
CA2877533C (en) 2012-06-22 2022-08-16 The Trustees Of Dartmouth College Novel vista-ig constructs and the use of vista-ig for treatment of autoimmune, allergic and inflammatory disorders
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014022759A1 (en) 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
PT2885010T (pt) 2012-08-16 2020-03-11 Ipierian Inc Métodos de tratamento de uma tauopatia
EP2888279A1 (de) 2012-08-22 2015-07-01 Glaxo Group Limited Anti-lrp6-antikörper
EP2892558B1 (de) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista-modulatoren zur diagnose und behandlung von krebs
WO2014058915A2 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
AU2013329421A1 (en) 2012-10-09 2015-04-30 Biogen Ma Inc. Combination therapies and uses for treatment of demyelinating disorders
AU2013334229B2 (en) 2012-10-25 2018-02-15 Bioverativ Usa Inc. Anti-complement C1s antibodies and uses thereof
WO2014066733A2 (en) 2012-10-25 2014-05-01 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
EP2914621B1 (de) 2012-11-05 2023-06-07 Foundation Medicine, Inc. Neuartige ntrk1-fusionsmoleküle und verwendungen davon
AU2013340449B2 (en) 2012-11-05 2017-11-30 Pfizer Inc. Spliceostatin analogs
SG11201503469WA (en) 2012-11-07 2015-06-29 Pfizer Anti-notch3 antibodies and antibody-drug conjugates
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2014100602A1 (en) 2012-12-20 2014-06-26 Hospital For Special Surgery Treatment of egf-receptor dependent pathologies
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
AU2013370171B2 (en) 2012-12-28 2018-09-13 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2961853B1 (de) 2013-02-28 2018-09-19 The Board of Regents of The University of Texas System Verfahren zur klassifizierung einer krebserkrankung als anfälligkeit für tmepai-gerichtete therapien und zur heilung solcher krebserkrankungen
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
US9023353B2 (en) 2013-03-13 2015-05-05 The Board Of Trustees Of The University Of Arkansas Anti-(+)—methamphetamine monoclonal antibodies
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
JP2016520527A (ja) 2013-03-14 2016-07-14 パーカシュ ギル， 細胞表面ｇｒｐ７８に結合する抗体を使用したがんの処置
EP2968370A4 (de) 2013-03-14 2016-09-21 Univ Maryland Mittel zur androgenrezeptor-abwärtsregelung und verwendungen davon
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res (Munich) Gmbh Moléculas de unión para bcma y cd3
BR112015023084A2 (pt) 2013-03-15 2017-11-21 Abbvie Biotechnology Ltd anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
RU2015144033A (ru) 2013-03-15 2017-04-26 Эббви Байотекнолоджи Лтд. Антитела против cd25 и их применения
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP3590922A1 (de) 2013-03-15 2020-01-08 Zymeworks Inc. Zytotoxische und antimitotische verbindungen und verfahren zur verwendung davon
ES2906615T3 (es) 2013-04-19 2022-04-19 Cytune Pharma Tratamiento derivado de citocinas con síndrome de fuga vascular reducido
KR20160013049A (ko) 2013-06-03 2016-02-03 노파르티스 아게 항-pd-l1 항체 및 mek 억제제 및/또는 braf 억제제의 조합물
EP3004877A4 (de) 2013-06-06 2017-04-19 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
JP6446443B2 (ja) 2013-06-10 2018-12-26 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US9587032B2 (en) 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
US9428748B2 (en) 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
EP3159695A3 (de) 2013-06-20 2017-07-05 The Trustees of The University of Pennsylvania Verfahren zur diagnose von bauchspeicheldrüsenkrebs
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2919477A1 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
JP2016528252A (ja) 2013-08-12 2016-09-15 トーカイ ファーマシューティカルズ， インコーポレイテッド アンドロゲン標的治療を使用する新生物障害の処置のためのバイオマーカー
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP6615100B2 (ja) 2013-09-24 2019-12-04 ザ ファインスタイン インスティチュート フォー メディカル リサーチ 低温誘導性ｒｎａ結合タンパク質活性を阻害するペプチド
EP3049085B9 (de) 2013-09-26 2021-08-18 Beth Israel Deaconess Medical Center, Inc. Sgk1 inhibitoren bei der behandlung von long-qt-syndrom
EP3049442A4 (de) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
WO2015057699A2 (en) 2013-10-15 2015-04-23 Seattle Genetics, Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
CA2928014A1 (en) 2013-11-15 2015-05-21 Institut Pasteur Method for detecting a molecular marker of plasmodium falciparum artemisinin resistance
EP3074420A2 (de) 2013-11-27 2016-10-05 Ipierian, Inc. Verfahren zur behandlung einer tauopathie
MX2016007533A (es) 2013-12-09 2016-12-14 Univ New York Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
WO2015091653A2 (en) 2013-12-17 2015-06-25 Westfaelische Wilhelms-Universitaet Muenster Means and methods for treating a pruritus-like skin-disease
SI3082878T1 (sl) 2013-12-19 2023-01-31 Seagen Inc. Metilen-karbamatni linkerji za uporabo s tarčnimi konjugati zdravila
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP2960252A1 (de) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase zur Behandlung von Immunosuppression
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
ES2920677T3 (es) 2013-12-24 2022-08-08 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-VISTA
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
WO2015103026A2 (en) 2014-01-03 2015-07-09 The Regents Of The University Of Michigan Treatment of neurological disorders
WO2015104711A1 (en) 2014-01-09 2015-07-16 Hadasit Medical Research Services And Development Ltd. Improved cell compositions and methods for cancer therapy
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015208814B2 (en) 2014-01-27 2018-11-01 Pfizer Inc. Bifunctional cytotoxic agents
EP3099719B1 (de) 2014-01-29 2020-04-01 Dana-Farber Cancer Institute, Inc. Antikörper gegen die muc1-c/extrazelluläre domäne (/muc1-c/ecd)
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106211773B (zh) 2014-02-11 2021-09-03 威特拉公司 用于登革病毒的抗体分子及其应用
CA2937753A1 (en) 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
US20170226192A1 (en) 2014-02-19 2017-08-10 Jody Berry Methods of modulating an immune response
EP2915569A1 (de) 2014-03-03 2015-09-09 Cytune Pharma Reinigungsverfahren für Il-15/Il-15Ralpha-basierte Konjugate
CN106103484B (zh) 2014-03-14 2021-08-20 诺华股份有限公司 针对lag-3的抗体分子及其用途
EP3119876A1 (de) 2014-03-19 2017-01-25 Pfizer Inc. Verfahren zur zellkultur
US20170174764A1 (en) 2014-03-27 2017-06-22 Yeda Research And Development Co. Ltd. T-cell receptor cdr3 peptides and antibodies
JP2017512759A (ja) 2014-04-10 2017-05-25 オービーアイ ファーマ インコーポレイテッド 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途
AU2015249374A1 (en) 2014-04-24 2016-12-01 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
CA2983794A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
EP3137502B1 (de) 2014-04-27 2020-07-29 FameWave Ltd. Humanisierte antikörper gegen ceacam1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
IL248511B (en) 2014-05-13 2022-07-01 Bavarian Nordic As Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
US10774387B2 (en) 2014-05-19 2020-09-15 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
EP3154585B1 (de) 2014-06-11 2022-02-23 Kathy A. Green Verwendung von vista-agonisten und antagonisten zur unterdrückung oder verbesserung der humoralen immunität
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016011383A1 (en) 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Methods for using exosomes to monitor transplanted organ status
JP6940406B2 (ja) 2014-07-25 2021-09-29 テラベクティＴｈｅｒａｖｅｃｔｙｓ キメラ抗原レセプター分子の制御的発現のためのレンチウイルスベクター
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
AU2015295242B2 (en) 2014-07-31 2020-10-22 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
EP3174901B1 (de) 2014-07-31 2019-06-26 Amgen Research (Munich) GmbH Optimierte artenübergreifende spezifische bispezifische einkettige antikörperkonstrukte
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
US10278986B2 (en) 2014-08-14 2019-05-07 The Regents Of The University Of Colorado, A Body Corporate Antibody-siRNA conjugates and uses therefor
CA2959336A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
US10961506B2 (en) 2014-09-04 2021-03-30 Stemcell Technologies Inc. Soluble antibody complexes for T cell or NK cell activation and expansion
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
CN106470697B (zh) 2014-09-16 2019-10-25 兴盟生物医药(苏州)有限公司 抗egfr抗体以及其用途
CN113416229A (zh) 2014-09-17 2021-09-21 酵活有限公司 细胞毒性和抗有丝分裂化合物、及其使用方法
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
EP3204119B1 (de) 2014-10-09 2021-06-09 Dana-Farber Cancer Institute, Inc. Mehrfach-variabler il-2-dosierungsplan zur behandlung von immunerkrankungen
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
EP3215527A4 (de) 2014-11-05 2018-04-18 Annexon, Inc. Humanisierte anti-komplementfaktor-c1q-antikörper und verwendungen davon
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CN107530423B (zh) 2015-01-14 2022-04-05 布里格姆及妇女医院股份有限公司 用抗lap单克隆抗体治疗癌症
US10975163B2 (en) 2015-01-15 2021-04-13 Oncoquest Pharmaceuticals Inc. Methods of increasing delivery of anti-cancer agents to targets
DK3254110T3 (da) 2015-02-03 2020-05-18 Ventana Med Syst Inc Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2016222599B2 (en) 2015-02-25 2020-03-19 The Board Of Regents Of The University Of Texas System Antibody-mediated neutralization of Marburg virus
US11155601B2 (en) 2015-03-06 2021-10-26 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
WO2016144673A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
AU2016238551B2 (en) 2015-03-20 2020-01-02 Pfizer Inc. Bifunctional cytotoxic agents containing the CTI pharmacophore
HUE061076T2 (hu) 2015-04-06 2023-05-28 Bioverativ Usa Inc Humanizált anti-C1s ellenanyagok alkalmazási eljárások
SG10201909308XA (en) 2015-04-17 2019-11-28 Amgen Res Munich Gmbh Bispecific antibody constructs for cdh3 and cd3
WO2016170022A1 (en) 2015-04-21 2016-10-27 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting znf555
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
TW201702271A (zh) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies
CN113940996A (zh) 2015-05-27 2022-01-18 Ucb生物制药私人有限公司 用于治疗神经系统疾病的方法
JP6948708B2 (ja) 2015-06-19 2021-10-13 センチュリオン バイオファーマ コーポレイション 薬物制御放出のための送達系
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
WO2017005734A1 (en) 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
CA2991264C (en) 2015-07-06 2023-10-10 Ucb Biopharma Sprl Tau-binding antibodies
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
EP4378957A2 (de) 2015-07-29 2024-06-05 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen pd-1
EP3964528A1 (de) 2015-07-29 2022-03-09 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
WO2017023861A1 (en) 2015-08-03 2017-02-09 The Regents Of The University Of California Compositions and methods for modulating abhd2 activity
BR112018002436A2 (pt) 2015-08-04 2018-09-18 Glaxosmithkline Ip Dev Ltd tratamento de combinação de usos de métodos destes
EP3331918A1 (de) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen und verwendungen und verfahren dafür
US20180222990A1 (en) 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
WO2017021792A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Biologicals Sa Tlr4 agonists and compositions thereof and their use in the treatment of cancer
TW201716084A (zh) 2015-08-06 2017-05-16 葛蘭素史克智慧財產發展有限公司 組合物及其用途與治療
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
JP2018528191A (ja) 2015-08-19 2018-09-27 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
WO2017037203A1 (en) 2015-09-02 2017-03-09 Immutep S.A.S. Anti-LAG-3 Antibodies
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
IL258121B2 (en) 2015-09-15 2024-01-01 Scholar Rock Inc Antipro/latent myostatin antibodies and their uses
CA3214798A1 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
WO2017062792A1 (en) 2015-10-07 2017-04-13 Obi Pharma, Inc. Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
US11161912B2 (en) 2015-10-13 2021-11-02 Technion Research & Development Foundation Limited Heparanase-neutralizing monoclonal antibodies
EP3362074B1 (de) 2015-10-16 2023-08-09 President and Fellows of Harvard College Pd-1-modulation in regulatorischen t-zellen zur regulierung von t-zelleffektorimmunreaktionen
CN116059350A (zh) 2015-10-27 2023-05-05 Ucb生物制药有限责任公司 使用抗-il-17a/f抗体的治疗方法
US20210106661A1 (en) 2015-10-29 2021-04-15 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
US11353458B2 (en) 2015-10-30 2022-06-07 Glaxosmithkline Intellectual Property Development Limited Prognostic method
US20180320136A1 (en) 2015-11-03 2018-11-08 GlycoMimitics, Inc. Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
US10233212B2 (en) 2015-11-03 2019-03-19 Industrial Technology Research Institute Compounds, linker-drugs and ligand-drug conjugates
JP6987068B2 (ja) 2015-11-09 2021-12-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 癌マーカーおよび治療標的としてのグリピカン２
EP3374391B1 (de) 2015-11-10 2024-04-17 Visterra, Inc. Antikörpermolekülarzneimittelkonjugate die an lipopolysaccharide binden und verwendungen davon
CN118027201A (zh) 2015-11-25 2024-05-14 威特拉公司 April的抗体分子及其应用
CA3006934A1 (en) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
CA3006000A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
KR20180094977A (ko) 2015-12-17 2018-08-24 노파르티스 아게 c-Met 억제제와 PD-1에 대한 항체 분자의 조합물 및 그의 용도
WO2017106806A1 (en) 2015-12-18 2017-06-22 Federica Cavallo COMPOSITIONS AND METHODS RELATED TO xCT PEPTIDES
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
EP3184544A1 (de) 2015-12-23 2017-06-28 Julius-Maximilians-Universität Würzburg Glycoprotein-v-inhibitoren zur verwendung als koagulansien
MX2018008369A (es) 2016-01-08 2019-05-15 Scholar Rock Inc Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
US10723727B2 (en) 2016-02-01 2020-07-28 Pfizer Inc. Tubulysin analogs and methods for their preparation
UA126656C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Гмбх Біспецифічна конструкція антитіла до psma і cd3, яке залучають t-клітини
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
MA43955B1 (fr) 2016-02-03 2022-02-28 Amgen Inc Anticorps anti-bcma et anti-cd3 bispécifiques de format bite
EP3410849B1 (de) 2016-02-05 2023-07-05 Institut Pasteur Verwendung von inhibitoren von adam12 als adjuvanzien in tumortherapien
TWI756204B (zh) 2016-02-12 2022-03-01 比利時商楊森製藥公司 抗ｖｉｓｔａ抗體及片段、其用途及鑑定其之方法
EP3207937A1 (de) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland Verfahren zur behandlung oder prävention von sepsis
WO2017151517A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
WO2017149538A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
US11921116B2 (en) 2016-03-09 2024-03-05 Memorial Sloan Kettering Cancer Center Enigma and CDH18 as companion diagnostics for CDK4 inhibitors
CN109562154A (zh) 2016-03-10 2019-04-02 爱普瑞希斯有限公司 带有修饰hsp70域的抗原结合融合蛋白
MX2018010948A (es) 2016-03-11 2019-06-20 Scholar Rock Inc INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS.
CA3011887A1 (en) 2016-03-14 2017-09-21 Stian FOSS Engineered immunoglobulins with altered fcrn binding
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
EP3430042B1 (de) 2016-03-17 2023-05-24 Numab Innovation AG Anti-tnf-alpha-antikörper und funktionale fragmente davon
CA3016870A1 (en) 2016-03-17 2017-09-21 Numab Innovation Ag Anti-tnf.alpha.-antibodies and functional fragments thereof
MA43715A (fr) 2016-03-17 2018-11-28 Numab Innovation Ag Anticorps anti-tnf et fragments fonctionnels correspondants
WO2017158436A1 (en) 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
PT3219727T (pt) 2016-03-17 2021-01-21 Tillotts Pharma Ag Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
RS61374B1 (sr) 2016-03-17 2021-02-26 Tillotts Pharma Ag Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
EP3433281A1 (de) 2016-03-21 2019-01-30 Elstar Therapeutics, Inc. Multispezifische und multifunktionelle moleküle und verwendungen davon
MA43835A (fr) 2016-03-25 2018-11-28 Seattle Genetics Inc Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
CA3018216A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulations of antibody molecules to dengue virus
BR112018070357A2 (pt) 2016-04-04 2019-01-29 Bioverativ Usa Inc anticorpos anticomplemento contra o fator bb e seus usos
US20190112572A1 (en) 2016-04-05 2019-04-18 Pfizer Inc. Cell culture process
JP7197078B2 (ja) 2016-04-08 2022-12-27 ジィールバイオ，インコーポレーテッド プレクチン１結合性抗体およびその使用
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
CN118108843A (zh) 2016-04-15 2024-05-31 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
TWI757291B (zh) 2016-05-11 2022-03-11 美商安美基公司 使用麩醯胺合成酶基因內互補載體直接選擇表現高水準異質蛋白的細胞
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017203051A1 (en) 2016-05-26 2017-11-30 University College Cork - National University Of Ireland, Cork An engineered gram positive bacterium
US11534496B2 (en) 2016-06-07 2022-12-27 The Brigham And Women's Hospital, Inc. Compositions and methods relating to T peripheral helper cells in autoantibody-associated conditions
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
US20190177438A1 (en) 2016-06-17 2019-06-13 Life Technologies Corporation Site-Specific Crosslinking of Antibodies
WO2017221072A2 (en) 2016-06-21 2017-12-28 University Of Oslo Hla binding vaccine moieties and uses thereof
KR20190039134A (ko) 2016-07-13 2019-04-10 바이오젠 엠에이 인코포레이티드 Lingo-1 길항제의 투약 섭생 및 탈수초성 질환의 치료를 위한 용도
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
US11858980B2 (en) 2016-08-02 2024-01-02 Visterra, Inc. Engineered polypeptides and uses thereof
US11712480B2 (en) 2016-08-03 2023-08-01 Pfizer Inc. Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
BR112019001945A2 (pt) 2016-08-09 2019-05-07 Seattle Genetics, Inc. composição de conjugado de fármaco aglutinante, formulação farmaceuticamente aceitável, métodos para tratar uma doença ou afecção hiperproliferativa, para inibir a multiplicação de uma célula tumoral ou célula cancerígena e para preparar uma composição de conjugado de fármaco aglutinado, e, composto
ES2919927T3 (es) 2016-08-10 2022-07-29 Pasteur Institut Métodos y reactivos para la detección del paludismo por Plasmodium falciparum resistente a la piperaquina
EP4371611A2 (de) 2016-08-15 2024-05-22 Novartis AG Regimes und verfahren zur behandlung von multipler sklerose mit ofatumumab
WO2018038684A1 (en) 2016-08-26 2018-03-01 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
EP3293271A1 (de) 2016-09-12 2018-03-14 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Marker und target als eine diagnosevariable und target zur therapie von metastatischem krebs
JP7466308B2 (ja) 2016-09-20 2024-04-12 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｕｓｐ１０バイオマーカーおよびモジュレーターを用いたａｍｌの同定、評価、予防および処置のための組成物および方法
CN118005799A (zh) 2016-09-23 2024-05-10 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
MX2019003727A (es) 2016-09-29 2019-08-05 Amgen Inc Proteinas de union a antigeno de baja viscosidad y metodos de prepararlas.
GB201616596D0 (en) 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
MX2019004259A (es) 2016-10-12 2019-09-27 Bioverativ Usa Inc Anticuerpos anti-c1s y metodos de uso de los mismos.
KR20190074292A (ko) 2016-10-18 2019-06-27 시애틀 지네틱스, 인크. 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
CA3045243A1 (en) 2016-12-01 2018-06-07 Glaxosmithkline Intellectual Property Development Limited Combination therapy
EP3548069A1 (de) 2016-12-01 2019-10-09 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie
JP7244987B2 (ja) 2016-12-14 2023-03-23 シージェン インコーポレイテッド 多剤抗体薬物コンジュゲート
CA3047230A1 (en) 2016-12-15 2018-06-21 The National Institute for Biotechnology in the Negev Ltd. Anti-pcna monoclonal antibodies and use thereof
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
JP7139332B2 (ja) 2016-12-23 2022-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法
US11542337B2 (en) 2016-12-23 2023-01-03 Bristol Myers Squibb Company Therapeutic immunoglobulin G4 for improved bioanalytical and bioprocessing properties
JP7360324B2 (ja) 2016-12-23 2023-10-12 ビステラ， インコーポレイテッド 結合ポリペプチドおよびそれを作製する方法
WO2018129395A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
WO2018129329A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
DK3565592T3 (da) 2017-01-06 2023-05-01 Scholar Rock Inc Behandling af stofskiftesygdomme ved inhibering af myostatinaktivering
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
US11890319B2 (en) 2017-01-18 2024-02-06 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
CN110461860A (zh) 2017-01-24 2019-11-15 辉瑞公司 卡奇霉素衍生物及其抗体药物缀合物
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
US20180221476A1 (en) 2017-02-06 2018-08-09 Oncoquest Nc. Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
US20190375847A1 (en) 2017-02-15 2019-12-12 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CN118063619A (zh) 2017-03-02 2024-05-24 诺华股份有限公司 工程化的异源二聚体蛋白质
BR112019018700A2 (pt) 2017-03-10 2020-04-07 Embera Neurotherapeutics Inc composições farmacêuticas e seus usos
CR20190468A (es) 2017-03-14 2019-12-17 Bioverativ Usa Inc Métodos para tratar enfermedades y trastornos mediados por completo
KR102619015B1 (ko) 2017-03-15 2023-12-28 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
CA3056182A1 (en) 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
US20200132673A1 (en) 2017-03-24 2020-04-30 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
AU2018237683A1 (en) 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
US11571459B2 (en) 2017-04-03 2023-02-07 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
WO2018195283A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CA3061206A1 (en) 2017-04-22 2018-10-25 Immunomic Therapeutics, Inc. Improved lamp constructs
BR112019022445A2 (pt) 2017-04-27 2020-05-12 Seattle Genetics, Inc. Composição de conjugado ligante-fármaco, formulação, método para inibir a multiplicação de uma célula tumoral ou célula cancerosa ou causar apoptose em uma célula tumoral ou cancerosa, e, composto de conector de fármaco
WO2018200533A1 (en) 2017-04-28 2018-11-01 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
CA3059769A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
EP3615068A1 (de) 2017-04-28 2020-03-04 Novartis AG Auf bcma abzielender wirkstoff und kombinationstherapie mit einem gamma-sekretase-inhibitor
KR20240027895A (ko) 2017-05-02 2024-03-04 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
AU2018261951A1 (en) 2017-05-05 2019-10-31 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
WO2018213665A1 (en) 2017-05-19 2018-11-22 Syndax Pharmaceuticals, Inc. Combination therapies
EP3630830A1 (de) 2017-05-23 2020-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Neuer cd73-antikörper, herstellung und verwendungen davon
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
US11325957B2 (en) 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
WO2018237157A1 (en) 2017-06-22 2018-12-27 Novartis Ag CD73 BINDING ANTIBODY MOLECULES AND USES THEREOF
EP3642240A1 (de) 2017-06-22 2020-04-29 Novartis AG Antikörpermoleküle gegen cd73 und verwendungen davon
CN111050791A (zh) 2017-06-27 2020-04-21 诺华股份有限公司 用于抗tim-3抗体的给药方案及其用途
US20210145828A1 (en) 2017-06-29 2021-05-20 Rutgers, The State University Of New Jersey Compositions And Methods Targeting G12 Signaling For Bronchodilator Therapy
EP3431496A1 (de) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
US20200172617A1 (en) 2017-07-20 2020-06-04 Novartis Ag Dosage regimens of anti-lag-3 antibodies and uses thereof
WO2019023661A1 (en) 2017-07-28 2019-01-31 Scholar Rock, Inc. SPECIFIC INHIBITORS OF TGF-BETA 1 LTBP COMPLEX AND USES THEREOF
WO2019025299A1 (en) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag METHOD OF HUMANIZATION BASED ON THREE DIMENSIONAL STRUCTURE
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019053611A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited POLY THERAPY FOR THE TREATMENT OF CANCER
EP3692066A2 (de) 2017-09-14 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlung von krebs
CA3075716A1 (en) 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
MA50239A (fr) 2017-09-15 2020-07-22 Amgen Inc Procédé de formulation pharmaceutique lyophilisée d'une protéine thérapeutique
KR20200047702A (ko) 2017-09-15 2020-05-07 브리스톨-마이어스 스큅 컴퍼니 관심 폴리펩티드 대규모 생산 동안의 온라인 바이오매스 정전용량 모니터링
ES2759622T3 (es) 2017-10-02 2020-05-11 Certest Biotec S L Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
BR112020005419A2 (pt) 2017-10-02 2020-09-29 Visterra, Inc. moléculas de anticorpo para cd138 e seus usos
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
SG11202003486UA (en) 2017-10-19 2020-05-28 Debiopharm Int Sa Combination product for the treatment of cancer
US20200331975A1 (en) 2017-10-20 2020-10-22 Institut Curie Dap10/12 based cars adapted for rush
US20200283485A1 (en) 2017-10-20 2020-09-10 Institut Curie Hook fusion protein for regulating the cellular trafficking of a target protein
CN111587123A (zh) 2017-11-09 2020-08-25 品通治疗有限公司 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
PT3717503T (pt) 2017-11-30 2024-01-16 Ladrx Corp Profármacos de ligação a albumina de derivados de auristatina e
KR20200117988A (ko) 2017-11-30 2020-10-14 센추리온 바이오파마 코포레이션 메이탄시노이드계 약물 전달 시스템
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
WO2019113464A1 (en) 2017-12-08 2019-06-13 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
JP7344206B2 (ja) 2017-12-11 2023-09-13 アムジェン インコーポレイテッド 二重特異性抗体製品のための連続製造プロセス
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
CN111954541A (zh) 2018-01-25 2020-11-17 Acm生物实验室私人有限公司 包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
WO2019155474A1 (en) 2018-02-12 2019-08-15 Hadasit Medical Research Services & Development Ltd. Modulation of slamf6 splice variants for cancer therapy
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
US11857565B2 (en) 2018-02-20 2024-01-02 Seagen Inc. Hydrophobic Auristatin F compounds and conjugates thereof
AU2019223076A1 (en) 2018-02-21 2020-10-08 Celgene Corporation BCMA-binding antibodies and uses thereof
EP3755712A1 (de) 2018-02-21 2020-12-30 Cell Design Labs, Inc. Chimäre transmembranrezeptoren und verwendungen davon
EP3530282A1 (de) 2018-02-27 2019-08-28 Diaccurate Therapeutische verfahren
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
KR20200133240A (ko) 2018-03-16 2020-11-26 브리스톨-마이어스 스큅 컴퍼니 단백질 생산 동안의 대사 효소 활성 및 디술피드 결합 환원
EP3775909B1 (de) 2018-03-26 2023-05-10 Glycanostics s.r.o. Mittel und verfahren zur glykoprofilierung eines proteins
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN111886023A (zh) 2018-04-24 2020-11-03 安源医药科技（上海）有限公司 针对tim-3的抗体及其用途
EP3790900A1 (de) 2018-05-09 2021-03-17 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Für menschliches nectin4 spezifische antikörper
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
US20210267973A1 (en) 2018-05-31 2021-09-02 Glaxosmithkline Intellectual Property Development Limited Combination of a type ii protein arginine methyltransferase inhibitor and an icos binding protein to treat cancer
CN112469441A (zh) 2018-05-31 2021-03-09 葛兰素史克知识产权开发有限公司 用icos结合蛋白和精氨酸甲基转移酶抑制剂的组合疗法
WO2019236739A1 (en) 2018-06-05 2019-12-12 Amgen Inc. Modulating antibody dependent cellular phagocytosis
TW202015740A (zh) 2018-06-07 2020-05-01 美商西雅圖遺傳學公司 喜樹鹼結合物
WO2019246293A2 (en) 2018-06-19 2019-12-26 Atarga, Llc Antibody molecules to complement component 5 and uses thereof
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
EP3818083A2 (de) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr-antikörpermoleküle und ihre verwendungen
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
JP2021531254A (ja) 2018-07-11 2021-11-18 スカラー ロック インコーポレイテッドScholar Rock, Inc. 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
ES2905160T3 (es) 2018-07-11 2022-04-07 Scholar Rock Inc Inhibidores selectivos de la isoforma TGFBeta1 y utilización de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
TW202021616A (zh) 2018-07-30 2020-06-16 美商安進公司 結合至ｃｄ３３和ｃｄ３的雙特異性抗體構建體之延長投與
EP3829633A1 (de) 2018-08-03 2021-06-09 Amgen Research (Munich) GmbH Antikörperkonstrukte für cldn18.2 und cd3
WO2020031087A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
WO2020030570A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
CA3109732A1 (en) 2018-08-27 2020-03-05 Affimed Gmbh Cryopreserved nk cells preloaded with an antibody construct
WO2020055900A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
US20220105176A1 (en) 2018-09-12 2022-04-07 Acm Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
AU2019346645A1 (en) 2018-09-27 2021-04-29 Marengo Therapeutics, Inc. CSF1R/CCR2 multispecific antibodies
CN112703204A (zh) 2018-09-28 2021-04-23 安进公司 针对可溶性bcma的抗体
WO2020070303A1 (en) 2018-10-05 2020-04-09 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
CA3116091A1 (en) 2018-10-16 2020-04-23 UCB Biopharma SRL Method for the treatment of myasthenia gravis
MX2021004603A (es) 2018-10-22 2021-09-08 Glaxosmithkline Ip Dev Ltd Dosificacion.
SG11202104010PA (en) 2018-10-23 2021-05-28 Scholar Rock Inc Rgmc-selective inhibitors and use thereof
WO2020089794A1 (en) 2018-10-31 2020-05-07 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
SG11202104918PA (en) 2018-11-20 2021-06-29 Bavarian Nordic As Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
EP3891292A1 (de) 2018-12-06 2021-10-13 Pfizer Inc. Zellen mit reduzierter inhibitorproduktion und verfahren zur verwendung davon
EP3897648B1 (de) 2018-12-20 2023-08-23 Novartis AG Erweiterte niedrigdosierungsschemata für mdm2-inhibitoren
JP2022519341A (ja) 2019-01-13 2022-03-23 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー． ヒトネクチン－２に特異的な抗体
MX2021009175A (es) 2019-01-30 2021-09-14 Scholar Rock Inc Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
WO2020160365A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Belantamab mafodotin in combination with pembrolizumab for treating cancer
EP3693063A1 (de) 2019-02-06 2020-08-12 Diaccurate Verfahren und zusammensetzungen zur behandlung von krebs
EP3924739A1 (de) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarker von progressiver multifokaler leukoenzephalopathie
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
EA202192146A1 (ru) 2019-02-15 2021-11-09 Интиграл Молекьюлар, Инк. Антитела к клаудину 6 и их применение
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
CN113423730B (zh) 2019-02-15 2024-01-05 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
SG11202109056TA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to calreticulin and uses thereof
CN114127112A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
JP2022521937A (ja) 2019-02-21 2022-04-13 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
CN114026122A (zh) 2019-02-21 2022-02-08 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
AU2020226904A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
EP3947457A1 (de) 2019-03-26 2022-02-09 ASLAN Pharmaceuticals Pte Ltd Behandlung mit verwendung von anti-il-13r-antikörper oder bindefragment davon
SG11202110732XA (en) 2019-03-29 2021-10-28 Atarga Llc Anti fgf23 antibody
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
WO2020208572A1 (en) 2019-04-10 2020-10-15 Glaxosmithkline Intellectual Property Development Limited Combination therapy with an anti bcma antibody and a gamma secretase inhibitor
CA3133333A1 (en) 2019-04-30 2020-04-30 Brian Scott GARRISON Chimeric receptors and methods of use thereof
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
TW202108177A (zh) 2019-05-10 2021-03-01 日商武田藥品工業股份有限公司 抗體藥物結合物
EP3983520A1 (de) 2019-06-13 2022-04-20 Amgen, Inc Automatisierte biomassebasierte perfusionssteuerung zur herstellung von biologika
EP3983442A2 (de) 2019-06-17 2022-04-20 Visterra, Inc. Humanisierte antikörpermoleküle gegen cd138 und verwendungen davon
WO2021016062A1 (en) 2019-07-19 2021-01-28 The Children's Hospital Of Philadelphia Chimeric antigen receptors containing glypican 2 binding domains
BR112022001415A2 (pt) 2019-07-26 2022-06-07 Visterra Inc Agentes interleucina-2 e os usos dos mesmos
WO2021018941A1 (en) 2019-07-31 2021-02-04 Glaxosmithkline Intellectual Property Development Limited Methods of treating cancer
WO2021024133A2 (en) 2019-08-06 2021-02-11 Glaxosmithkline Intellectual Property Development Limited Biopharmacuetical compositions and related methods
WO2021023860A1 (en) 2019-08-07 2021-02-11 Db Biotech, As Improved horseradish peroxidase polypeptides
CN114555637A (zh) 2019-08-12 2022-05-27 比昂生物制剂公司 针对ilt2的抗体及其用途
EP4025303A1 (de) 2019-09-04 2022-07-13 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Herv-inhibitoren zur verwendung bei der behandlung von tauopathien
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021046289A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
MX2022002981A (es) 2019-09-10 2022-04-06 Amgen Inc Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
EP3792632A1 (de) 2019-09-16 2021-03-17 Vito NV Immuntherapiemarker
AR120079A1 (es) 2019-09-19 2022-02-02 Seattle Genetics Inc Liberación selectiva de fármacos de conjugados internalizados de compuestos biológicamente activos
AU2020355614A1 (en) 2019-09-27 2022-04-14 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
WO2021059075A1 (en) 2019-09-27 2021-04-01 Janssen Biotech, Inc. Anti-ceacam antibodies and uses thereof
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
JP2022550851A (ja) 2019-10-04 2022-12-05 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
CA3153850A1 (en) 2019-10-18 2021-04-22 Teri Heiland Improved lamp constructs comprising cancer antigens
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
AU2020370832A1 (en) 2019-10-21 2022-05-19 Novartis Ag TIM-3 inhibitors and uses thereof
EP4058485A1 (de) 2019-11-13 2022-09-21 Amgen Inc. Verfahren zur verringerung der aggregatbildung bei der nachgelagerten verarbeitung von bispezifischen antigen-bindenden molekülen
WO2021099586A1 (en) 2019-11-20 2021-05-27 Bavarian Nordic A/S Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
CN115175937A (zh) 2019-12-20 2022-10-11 诺华股份有限公司 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
WO2021127528A1 (en) 2019-12-20 2021-06-24 Amgen Inc. Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
GB201919058D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
GB201919062D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
EP4081554A1 (de) 2019-12-27 2022-11-02 Affimed GmbH Verfahren zur herstellung eines bispezifischen fcyriii-x-cd30-antikörper-konstrukts
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
AU2021205893A1 (en) 2020-01-08 2022-06-23 Synthis Therapeutics, Inc. ALK5 inhibitor conjugates and uses thereof
MX2022008609A (es) 2020-01-11 2022-11-10 Scholar Rock Inc Inhibidores de tgf¿ y uso de los mismos.
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
TW202140553A (zh) 2020-01-13 2021-11-01 美商威特拉公司 C5ar1抗體分子及其用途
KR20220128389A (ko) 2020-01-17 2022-09-20 노파르티스 아게 골수이형성 증후군 또는 만성 골수단핵구성 백혈병을 치료하는데 사용하기 위한 tim-3 억제제 및 저메틸화제를 포함하는 조합물
EP4093771A1 (de) 2020-01-22 2022-11-30 Amgen Research (Munich) GmbH Kombinationen von antikörperkonstrukten und inhibitoren des zytokinfreisetzungssyndroms und verwendungen davon
JP2023512023A (ja) 2020-01-28 2023-03-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 併用療法及びその使用及び方法
GB202001447D0 (en) 2020-02-03 2020-03-18 Ucb Biopharma Sprl Antibodies
US20210283125A1 (en) 2020-02-25 2021-09-16 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
CA3175275A1 (en) 2020-03-19 2021-09-23 Amgen Inc. Antibodies against mucin 17 and uses thereof
US20210311054A1 (en) 2020-04-01 2021-10-07 Institut Pasteur Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
US11815513B2 (en) 2020-04-01 2023-11-14 Institut Pasteur Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
CA3178465A1 (en) 2020-04-03 2021-10-07 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR20220164787A (ko) 2020-04-06 2022-12-13 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 암 및 감염의 치료를 위한 NKp46에 대한 항체 및 이의 작제물
JP2023520930A (ja) 2020-04-10 2023-05-22 シージェン インコーポレイテッド 電荷多様性リンカー
US20230131598A1 (en) 2020-04-14 2023-04-27 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
EP4136113A1 (de) 2020-04-14 2023-02-22 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlung für krebs mit anti-icos- und anti-pd1-antikörpern, optional mit anti-tim3-antikörpern
EP4136105A1 (de) 2020-04-14 2023-02-22 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlung für krebs auf basis eines icos-antikörpers und eines pd-l1-antikörper-tgf-beta-rezeptor-fusionsproteins
CN115996949A (zh) 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
CA3176434A1 (en) 2020-04-17 2021-10-21 Zoetis Services Llc Feline antibody variants
WO2021217085A1 (en) 2020-04-24 2021-10-28 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
JP2023523794A (ja) 2020-05-01 2023-06-07 ノバルティス アーゲー 人工操作免疫グロブリン
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
AU2021281554A1 (en) 2020-05-29 2022-12-15 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3
WO2021247908A1 (en) 2020-06-03 2021-12-09 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
MX2022016591A (es) 2020-06-24 2023-04-20 Visterra Inc Moléculas de anticuerpo contra april y usos de las mismas.
EP4172193A1 (de) 2020-06-29 2023-05-03 Zoetis Services LLC Katzenantikörpervarianten zur verbesserung der stabilität
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
EP4179333A1 (de) 2020-07-10 2023-05-17 Institut Pasteur Verwendung von gdf11 zur diagnose und behandlung von angstzuständen und depression
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
WO2022031978A1 (en) 2020-08-06 2022-02-10 Bioverativ Usa Inc. Inflammatory cytokines and fatigue in subject with a complement mediated disease
JP2023537396A (ja) 2020-08-12 2023-08-31 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2022046922A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
EP4204458A1 (de) 2020-08-26 2023-07-05 Marengo Therapeutics, Inc. Verfahren zum nachweis von trbc1 oder trbc2
EP4204021A1 (de) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Verfahren zur behandlung von psma-exprimierenden krebsarten
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
JP2023540082A (ja) 2020-09-04 2023-09-21 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー ＳＡＲＳ－ＣｏＶ－２ワクチン及び抗体
US20240053339A1 (en) 2020-09-21 2024-02-15 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
CN116438196A (zh) 2020-09-28 2023-07-14 硕腾服务有限责任公司 犬抗体变体
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
IL301414A (en) 2020-09-29 2023-05-01 Zoetis Services Llc Feline antibody variants
AU2021357841A1 (en) 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
JP2023547795A (ja) 2020-10-15 2023-11-14 ユーシービー バイオファルマ エスアールエル Ｃｄ４５を多量体化する結合分子
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
WO2022089767A1 (en) 2020-11-02 2022-05-05 UCB Biopharma SRL Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
WO2022096704A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Antigen binding domain with reduced clipping rate
AU2021374839A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
JP2023547661A (ja) 2020-11-06 2023-11-13 アムジエン・インコーポレーテツド Ｃｄ３に結合するポリペプチド構築物
CR20230235A (es) 2020-11-06 2023-10-05 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
JP7397996B2 (ja) 2020-11-09 2023-12-13 武田薬品工業株式会社 抗体薬物コンジュゲート
AU2021382704A1 (en) 2020-11-20 2023-06-08 Zoetis Services Llc Bovine antibody variants
MX2023006599A (es) 2020-12-04 2023-06-19 Visterra Inc Metodos de uso de agentes de interleucina-2.
AU2021395729A1 (en) 2020-12-07 2023-07-13 UCB Biopharma SRL Multi-specific antibodies and antibody combinations
KR20230118128A (ko) 2020-12-07 2023-08-10 유씨비 바이오파마 에스알엘 인터루킨-22에 대한 항체
EP4263596A1 (de) 2020-12-18 2023-10-25 Zoetis Services LLC Mutationen in konstanten regionen von felinen antikörpern
CN117425500A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗dll3抗体-药物缀合物
AU2022207708A1 (en) 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
CA3207893A1 (en) 2021-01-15 2022-07-21 Seagen Inc. Immunomodulatory antibody-drug conjugates
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
TW202245825A (zh) 2021-01-20 2022-12-01 美商威特拉公司 介白素-2藥劑及其用途
JP2024504696A (ja) 2021-01-20 2024-02-01 バイオアントレ エルエルシー Ｃｔｌａ４結合性タンパク質およびがんを処置する方法
EP4281079A1 (de) 2021-01-22 2023-11-29 Royal College of Surgeons in Ireland Behandlung von coronavirus
CN116802205A (zh) 2021-01-28 2023-09-22 硕腾服务有限责任公司 犬抗体恒定区中的突变
JP2024505049A (ja) 2021-01-29 2024-02-02 ノバルティス アーゲー 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
JP2024506300A (ja) 2021-02-03 2024-02-13 シージェン インコーポレイテッド 免疫刺激化合物及びコンジュゲート体
EP4291580A1 (de) 2021-02-11 2023-12-20 Nectin Therapeutics Ltd. Antikörper gegen cd112r und verwendungen davon
WO2022182872A2 (en) 2021-02-24 2022-09-01 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
IL305575A (en) 2021-03-02 2023-10-01 Dana Farber Cancer Inst Inc Methods for treating red blood cell disorders
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
KR20230158006A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4314060A1 (de) 2021-03-31 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Antigenbindende proteine und kombinationen davon
CN117241828A (zh) 2021-03-31 2023-12-15 美国比奥维拉迪维股份有限公司 减少冷凝集素病患者的手术相关溶血
EP4067381A1 (de) 2021-04-01 2022-10-05 Julius-Maximilians-Universität Würzburg Neue tnfr2-bindende moleküle
WO2022212831A1 (en) 2021-04-02 2022-10-06 Amgen Inc. Mageb2 binding constructs
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
WO2022218957A1 (en) 2021-04-12 2022-10-20 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
AR125732A1 (es) 2021-05-03 2023-08-09 UCB Biopharma SRL Anticuerpos anti-trem1
AU2022269312A1 (en) 2021-05-06 2023-10-19 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
JP2024520562A (ja) 2021-05-28 2024-05-24 シージェン インコーポレイテッド アントラサイクリン抗体コンジュゲート
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
AU2022299185A1 (en) 2021-06-23 2024-01-25 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
EP4362977A1 (de) 2021-06-29 2024-05-08 Seagen Inc. Verfahren zur behandlung von krebs mit einer kombination aus einem nichtfucosylierten anti-cd70-antikörper und einem cd47-antagonisten
KR20240034234A (ko) 2021-07-14 2024-03-13 2세븐티 바이오, 인코포레이티드 항체로부터의 결합 도메인에 융합된 조작된 t 세포 수용체
EP4376958A1 (de) 2021-07-30 2024-06-05 Affimed GmbH Duplexkörper
CN117794954A (zh) 2021-08-03 2024-03-29 葛兰素史密斯克莱知识产权发展有限公司 生物药物组合物和稳定同位素标记肽图谱方法
GB202111905D0 (en) 2021-08-19 2021-10-06 UCB Biopharma SRL Antibodies
WO2023025927A1 (en) 2021-08-26 2023-03-02 Glycanostics S.R.O Glycoprotein biomarkers for diagnosing cancer
CA3231890A1 (en) 2021-09-14 2023-03-23 Jan Tkac Use of lectins to determine mammaglobin-a glycoforms in breast cancer
WO2023044483A2 (en) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
GB202115122D0 (en) 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
TW202333784A (zh) 2021-10-29 2023-09-01 新加坡商亞獅康私人有限公司 抗ｉｌ１３ｒ抗體調配物
CA3233696A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
CA3237018A1 (en) 2021-11-03 2023-05-11 Joachim Koch Bispecific cd16a binders
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20230348614A1 (en) 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
CA3238574A1 (en) 2021-12-01 2023-06-08 Gregory Babcock Methods of using interleukin-2 agents
WO2023105528A1 (en) 2021-12-12 2023-06-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to ceacam1
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023140780A1 (en) 2022-01-24 2023-07-27 Aslan Pharmaceuticals Pte Ltd. Method of treating inflammatory disease
WO2023148598A1 (en) 2022-02-02 2023-08-10 Pfizer Inc. Cysteine prototrophy
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
TW202337905A (zh) 2022-02-23 2023-10-01 新加坡商亞獅康私人有限公司 抗il13r抗體之糖基化形式
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
TW202400637A (zh) 2022-04-25 2024-01-01 美商威特拉公司 April之抗體分子及其用途
WO2023215740A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory antibody-drug conjugates
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
WO2023223092A1 (en) 2022-05-18 2023-11-23 Institut Pasteur Identification of a human circovirus
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2023245048A1 (en) 2022-06-15 2023-12-21 Bioverativ Usa Inc. Anti-complement c1s antibody formulation
EP4296279A1 (de) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
US20240025978A1 (en) 2022-06-24 2024-01-25 Bioverativ Usa Inc. Methods for treating complement-mediated diseases
GB202210679D0 (en) 2022-07-21 2022-09-07 Dualyx Nv Binding molecules targeting il-12rb2
WO2024023735A1 (en) 2022-07-27 2024-02-01 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024030976A2 (en) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions and methods for crossing the blood brain barrier
WO2024030577A1 (en) 2022-08-03 2024-02-08 Seagen Inc. Immunostimulatory anti-pd-l1-drug conjugates
EP4321522A1 (de) 2022-08-12 2024-02-14 Seagen Inc. Zytotoxische verbindungen und konjugate davon
WO2024043837A1 (en) 2022-08-26 2024-02-29 Aslan Pharmaceuticals Pte Ltd High concentration anti-il13r antibody formulation
WO2024054157A1 (en) 2022-09-06 2024-03-14 Aslan Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT373280B (de) * 1977-11-08 1984-01-10 Genentech Inc Verfahren zur erzeugung eines spezifischen polypeptids aus einem mikrobiellen rekombinations -clonbildungstraeger
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4464465A (en) * 1982-04-05 1984-08-07 Genetic Systems Corporation Cell-driven viral transfer in eukaryotes
IT1203672B (it) * 1982-05-12 1989-02-15 Harvard College Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
US4520226A (en) * 1982-07-19 1985-05-28 The United States Of America As Represented By The Department Of Health And Human Services Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates
JPS5965099A (ja) * 1982-10-05 1984-04-13 Takeda Chem Ind Ltd 発現用プロモ−タ−およびその用途
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法

Also Published As

Publication number Publication date
GB2177096B (en) 1989-05-17
ATE92959T1 (de) 1993-08-15
EP0194276A1 (de) 1986-09-17
JPH10155482A (ja) 1998-06-16
DE3587524D1 (de) 1993-09-16
JP2714786B2 (ja) 1998-02-16
GB8608827D0 (en) 1986-05-14
DE3587524T3 (de) 2002-06-20
EP0194276B2 (de) 2002-01-16
EP0194276B1 (de) 1993-08-11
JP2865645B2 (ja) 1999-03-08
WO1986001533A1 (en) 1986-03-13
JPS62500352A (ja) 1987-02-19
GB2177096A (en) 1987-01-14
GB8422238D0 (en) 1984-10-10

Similar Documents

Publication Publication Date Title
DE3587524D1 (de) Herstellung von chimaeren antikoerpern.
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
GB2137631B (en) Multichain polypeptides and processes for their production
KR920000789A (ko) 면역글로불린 부분을 갖는 융합 단백질, 이의 제조방법 및 용도
DE68921364D1 (de) Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA.
KR880006357A (ko) 인터류킨-i에 대한 항체
FR14C0070I1 (fr) Procede de la production des anticorps humanises
DE60039596D1 (de) Verfahren zur herstellung von monoklonalen antikörpern
ATE137802T1 (de) Monoklonaler antikörper, der mit einer neuen hla- determinante auf mhc-klasse-i-moleküle reagiert, und verfahren zur aktivierung von lymphozyten
IL93118A0 (en) Expression vectors,cells transformed thereby and their use in the production of chimeric monoclonal antibodies
ATE197068T1 (de) Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
MX26714A (es) Procedimiento para la preparacion de albumina de SUERO HUMANO VECTOR Y PLASMIDO USADOS ASI COMO LEVADURA METILOTROFICA TRANSFORMADA OBTENIDA
DE3581288D1 (de) Antileishmania monoklonale antikoerper, diese antikoerper ausscheidende hybridomas, von diesen antikoerpern erkannte leishmaniaantigene, verfahren zur herstellung und verwendung von diesen monoklonalen antikoerpern und antigenen.
PT733643E (pt) Polipeptido proteico membranar possuindo funcao de suporte do crescimento de pre-celulas b e gene para este
ES2075068T3 (es) Procedimiento de preparacion de una proteina mediante levaduras que utiliza un sistema inducible, vectores y cepas transformadas correspondientes.
ES2109225T3 (es) Anticuerpos, su produccion y uso.
DE68925044T2 (de) Herstellung von Fusionsproteinen oder -polypeptiden
Pénit et al. Purification and properties of chick terminal deoxynucleotidyl transferase (TdT)
SE8903865D0 (sv) Expression of heterologous proteins using eukaryotic cells
EP0287012A3 (de) Monoklonaler Anti-R-Binder-Antikörper, Verfahren zu seiner Herstellung und seine Verwendung
ATE239754T1 (de) An nukleinsäure gebundenes polypeptid, verfahren zur herstellung eines an nukleinsäure gebundenen polypeptides und immunoassay, in dem dieses polypeptid verwendung findet
IE871932L (en) Method for the preparation of proteins with factor viii¹activity by microbial host cells, expression vectors, host¹cells, antibodies

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings